Cyclerion Therapeutics Inc
NASDAQ:CYCN

Watchlist Manager
Cyclerion Therapeutics Inc Logo
Cyclerion Therapeutics Inc
NASDAQ:CYCN
Watchlist
Price: 1.34 USD 5.51% Market Closed
Market Cap: 5.3m USD

Net Margin
Cyclerion Therapeutics Inc

-77%
Current
-3 030%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-77%
=
Net Income
-2.2m
/
Revenue
2.9m

Net Margin Across Competitors

No Stocks Found

Cyclerion Therapeutics Inc
Glance View

Market Cap
5m USD
Industry
Biotechnology

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2019-03-18. The firm's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.

CYCN Intrinsic Value
3.09 USD
Undervaluation 57%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-77%
=
Net Income
-2.2m
/
Revenue
2.9m
What is the Net Margin of Cyclerion Therapeutics Inc?

Based on Cyclerion Therapeutics Inc's most recent financial statements, the company has Net Margin of -77%.

Back to Top